A groundbreaking PrEP injection could revolutionize HIV prevention. ViiV Healthcare's "cabotegravir ultra long-acting" (CAB-ULA) requires just three annual injections, promising enhanced protection. Initially FDA-approved in 2021 for bi-monthly injections, the drug is now being trialed for four-month intervals. ViiV presented promising trial results at the CROI 2024 conference, indicating its potential efficacy. If successful, this advancement could significantly improve PrEP adherence and accessibility, offering a game-changing solution in the fight against HIV transmission. #Queer Up Health